

# Kathryn Elisa Burns

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9551596/publications.pdf>

Version: 2024-02-01

23  
papers

869  
citations

1307594

7  
h-index

794594

19  
g-index

23  
all docs

23  
docs citations

23  
times ranked

2222  
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of a thymine challenge test and endogenous uracil dihydrouracil levels for assessment of fluoropyrimidine toxicity risk. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 711-716.	2.3	3
2	Cytochrome P450 in GtoPdb v.2021.2. IUPHAR/BPS Guide To Pharmacology CITE, 2021, 2021, .	0.2	3
3	Cyclophosphamide bioactivation pharmacogenetics in breast cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 533-542.	2.3	10
4	CYP2 family: physiological enzymes subset in GtoPdb v.2021.2. IUPHAR/BPS Guide To Pharmacology CITE, 2021, 2021, .	0.2	0
5	A systematic review of inter-individual differences in the DNA repair processes involved in melphalan monoadduct repair in relation to treatment outcomes. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 755-769.	2.3	9
6	Severe 5-Fluorouracil-Associated Gastrointestinal Toxicity Unexplained by Dihydropyrimidine Dehydrogenase Deficiency and Renal Impairment: Should We Be Investigating Other Elimination Pathways to Assess the Risk of 5-Fluorouracil Toxicity?. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2021, 46, 817-820.	1.6	1
7	Intracellular activation of 4-hydroxycyclophosphamide into a DNA-alkylating agent in human leucocytes. <i>Xenobiotica</i> , 2021, 51, 1188-1198.	1.1	1
8	THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Enzymes. <i>British Journal of Pharmacology</i> , 2021, 178, S313-S411.	5.4	320
9	Testing for dihydropyrimidine dehydrogenase deficiency in New Zealand to improve the safe use of 5-fluorouracil and capecitabine in cancer patients. <i>New Zealand Medical Journal</i> , 2021, 134, 120-128.	0.5	1
10	A case-control study to assess the ability of the thymine challenge test to predict patients with severe to life threatening fluoropyrimidine-induced gastrointestinal toxicity. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 155-164.	2.4	4
11	Circulating microRNA as biomarkers of clozapine-induced cardiotoxicity. <i>Biomarkers</i> , 2020, 25, 76-85.	1.9	6
12	A simple ex vivo bioassay for 5-FU transport into healthy buccal mucosal cells. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 739-748.	2.3	2
13	THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Enzymes. <i>British Journal of Pharmacology</i> , 2019, 176, S297-S396.	5.4	423
14	The importance of both <i>CYP2C19</i> and <i>CYP2B6</i> germline variations in cyclophosphamide pharmacokinetics and clinical outcomes. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1925-1934.	2.4	28
15	A higher throughput assay for quantification of melphalan-induced DNA damage in peripheral blood mononuclear cells. <i>Scientific Reports</i> , 2019, 9, 18912.	3.3	4
16	Cytochrome P450 (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide To Pharmacology CITE, 2019, 2019, .	0.2	1
17	Indirect regulation of <i>CYP2C19</i> gene expression via DNA methylation. <i>Xenobiotica</i> , 2018, 48, 781-792.	1.1	3
18	Transport of 5-fluorouracil into primary human cells. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO4-10-8.	0.0	0

#	ARTICLE	IF	CITATIONS
19	Human liver degradation of 5-fluorouracil: endogenous uracil may result in phenoconversion of dihydropyrimidine dehydrogenase activity. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO4-10-1.	0.0	0
20	High CYP2C19 phenotypic variability in gastrointestinal cancer patients. Cancer Chemotherapy and Pharmacology, 2016, 77, 195-204.	2.3	6
21	CYP2C19 genotypeâ€“phenotype discordance in patients with multiple myeloma leads to an acquired loss of drug-metabolising activity. Cancer Chemotherapy and Pharmacology, 2014, 73, 651-655.	2.3	16
22	Abstract 5548: Genotype-phenotype discordance of the hepatic drug metabolism enzyme CYP2C19 in gastrointestinal cancer patients. , 2014, , .		0
23	Molecular mechanisms of genetic variation and transcriptional regulation of CYP2C19. Frontiers in Genetics, 2012, 3, 206.	2.3	28